Quote this publication Share Print


Opinions on drugs - Posted on Dec 08 2009

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication "Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen".


Clinical Benefit


The actual benefit of XELODA is substantial.

Clinical Added Value

no clinical added value

Given the lack of data showing Xeloda to be superior to 5-fluorouracil, the Committee i considers that Xeloda does not provides IAB versus this comparator.

Contact Us

Évaluation des médicaments